I have worked as a research scientist and biotechnology innovator and entrepreneur focusing on cell biology pertaining to oncology. The work has proven to be impactful in basic and translational applications. Notable contributions include the discoveries that the survival kinase and pivotal cancer drug target AKT directly phosphorylates caspase 9 regulating its activity. Other work showed for the first time that caspase cleavage of the stress kinase MEKK1 activates that proteins kinase activity. I helped to start and develop several biology companies including a publicly traded company, Merrimack Pharmaceuticals, that achieved FDA approval for pancreatic cancer therapy, Onivyde® Following that, with co-founders Eutropics Pharmaceuticals was founded to develop novel cancer therapeutics with a companion predictive biomarker diagnostic platform (PRIMABS -Dx). The Eutropics diagnostic platform provides a completely novel method for measuring cellular features of individual patient’s cancer cells that identify sensitivities to particular drug treatments. This platform has the potential to bring an innovative and impactful personalized medicine approach.